A phase II trial of JDQ443 in <i>KRAS G12C</i>-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an <i>STK11</i> co-mutation
Authors
Lindsay, Colin RVeluswamy, R.
Castro, G.
Tan, D. S. W.
Caparica, R.
Glaser, S.
Malhotra, S.
Boran, A.
Felip, E.
Affiliation
The Christie Hospital NHS Foundation Trust, ManchesterIssue Date
2023
Metadata
Show full item recordCitation
Lindsay CR, Veluswamy R, Castro G, Tan DSW, Caparica R, Glaser S, et al. A phase II trial of JDQ443 in <i>KRAS G12C</i>-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an <i>STK11</i> co-mutation. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005506.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.TPS9158Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS9158Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.TPS9158